| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01a96e8bbea00eeaa0b50c2a0c000dba |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3517 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1851 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 |
| filingDate |
2008-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9adeae08705f0236db3a3963f6db7d95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78ca98050b04971e7eaea327a3332050 |
| publicationDate |
2010-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010310473-A1 |
| titleOfInvention |
Targeting Brain Cells Via Ophthalmic Delivery |
| abstract |
It is disclosed here that nucleic acid-based agents can be delivered to the brain of a human or non-human animal having a leakage in the blood brain barrier by administering the agents through the eye. Brain tissues and cells can be imaged in vivo (e.g., by magnetic resonance imaging) by linking a contrast agent to a targeting nucleic acid that can hybridize to a target nucleic acid located at the brain site to be imaged and administering the contrast agentltargeting nucleic acid conjugate through the eye. Similarly, a nucleic acid based drug (e.g., as an antisense nucleic acid or a therapeutic agent linked to a targeting nucleic acid that can hybridize to a target nucleic located at a disease site in the brain) can be administered through the eye to treat a brain disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015073773-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10406250-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021087445-A1 |
| priorityDate |
2007-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |